Compare Kraft Heinz Co (KHC) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kraft Heinz Co vs Natera Inc. Common Stock — how do they compare? Kraft Heinz Co trades at $22.79 (market cap $26.60B), while Natera Inc. Common Stock trades at $394.6 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 2.1× Kraft Heinz Co's market cap, and Kraft Heinz Co pays a 7.13% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kraft Heinz Co for 129 Days and Natera Inc. Common Stock for 0 Days on average.
| KHC | NTRA | |
|---|---|---|
Market Cap | $26.60B | $57.03B |
Volume | 11,136,448 | 1,131,157 |
Sector | Consumer Staples | Health |
52-Week High | $27.62 | $425.64 |
52-Week Low | $21.21 | $179.42 |
Typical Hold Time | 129 Days | 0 Days |
Enterprise Value | $42.92B | $56.18B |
Dividend Yield | 7.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kraft Heinz (KHC) trades at $22.70, up 1.11% on the day, with a bearish technical signal despite recent earnings beats. The stock shows mixed fundamentals, including a negative net income margin of -13.64% for 2025 but a low P/B of 0.74, suggesting potential undervaluation. Recent news highlights the company's $700 million reinvestment plan and new product launches like Philadelphia cream cheese flavors to revive brands amid volume challenges.
The outlook remains cautious due to persistent profitability issues and high debt, though the dividend yield near 6.5% and analyst consensus price target of $24.11 offer some upside. Key risks include execution of the turnaround strategy and competitive pressures in the consumer goods sector.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
